Perspective Therapeutics Highlights Progress in Radioligand Oncology Pipeline

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialPerspective Therapeutics ( (CATX) ) has shared an announcement. On January 14, 2026, Perspective Therapeutics updated its corporate presentation to highlight progress on its 212Pb-based radioligand platform and expanding oncology pipeline. The company detailed three ongoing Phase 1/2a clinical programs—VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma targeting MC1R, and PSV359 for FAP-α–expressing solid tumors—all of which have shown early signals of anti-tumor activity and manageable safety profiles. It also emphasized its secured clinical supply, commercial-scale manufacturing build-out, and strong IP coverage, positioning the company to potentially advance registration-enabling studies and to compete more aggressively in the growing solid tumor radiopharmaceutical market, with additional Phase 1/2 data from all three programs expected in 2026. The most recent analyst rating on (CATX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page. Spark’s Take on CATX Stock According to Spark, TipRanks’ AI Analyst, CATX is a Neutral. The score is held down primarily by very weak financial performance (large losses and significant cash burn despite minimal revenue), which dominates the risk profile. Technicals are moderately supportive in the near term, and corporate updates are encouraging on clinical progress, but valuation remains unattractive/unclear due to negative earnings and no dividend. To see Spark’s full report on CATX stock, click here. More about Perspective Therapeutics Perspective Therapeutics is an oncology-focused radiopharmaceutical company developing next-generation radioligand therapies that use lead-212 (212Pb) isotopes and proprietary chelators to improve targeted delivery and safety. The company is building an end-to-end manufacturing capability and a wholly owned pipeline aimed primarily at solid tumors, including neuroendocrine tumors, melanoma and other advanced solid cancers, supported by a broad intellectual property portfolio across the radiopharmaceutical value chain. Average Trading Volume: 1,685,906 Technical Sentiment Signal: Sell Current Market Cap: $179.2M For a thorough assessment of CATX stock, go to TipRanks’ Stock Analysis page.